- Home
- ARCT vs IPHA Comparison
ARCT vs IPHA Comparison
Compare ARCT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARCT | IPHA |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.6M | 169.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ARCT | IPHA |
|---|---|---|
| Price | $7.55 | $1.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $38.44 | $5.00 |
| AVG Volume (30 Days) | ★ 510.7K | 18.3K |
| Earning Date | 03-05-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,601,000.00 | $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.85 | $1.63 |
| 52 Week High | $24.17 | $2.63 |
Technical Indicators
Market Signals| Indicator | ARCT | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | N/A |
| Support Level | $7.00 | N/A |
| Resistance Level | $7.95 | N/A |
| Average True Range (ATR) | 0.37 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 30.00 | 0.00 |
Price Performance
Historical ComparisonAbout ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.